BHR Pharmaceuticals logo link to Home Page
 
 
 
 
 
 
 
 
   
   
   
   
ImmunoDip

People with diabetes are at high risk of cardiovascular disease (CVD)

Tight control of hypertension reduces the risk of cardiovascular events

Studies show that CVD can be reduced by treating hyperlipideamia

Early detection of microalbuminuria alerts the physician to the need for immediate intervention slowing down the progression of renal disease

Preventing / delaying progression to End-Stage Renal Disease (ESRD) saves the NHS £12,000 to £30,000 per patient per year * [*Nottingham City Hospital]

Arterial risk levels from measurement of urine albumin excretion* [*European Diabetes Policy Group]

Risk
Albumin
(mg/l)
Albumin : Creatinine ratio
(mg/mmol)
Men
Women
High
>15
>2.5
>3.5
BHR Pharmaceuticals Ltd
41, Centenary Business Centre, Hammond Close, Nuneaton, Warwickshire CV11 6RY
: t : +44 (0) 870 0349 606 : : f : +44 (0) 870 0349 607 : : e : info@bhr.co.uk :